You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

36 search results for: disease background

expert video

Pathophysiology of Bullous Pemphigoid

4 min

Dermatology

Join Dr. Schmidt as he describes the pathophysiology of bullous pemphigoid, as well as novel research avenues to better understand this complicated disease.

expert video

Type 2 Inflammation

2 min

Dermatology

In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Peter Leo, MD and Dr. Amy Paller, MD discusses the multifaceted nature of atopic diseases, including environmental triggers, key Type 2 inflammatory mechanisms, and associated health risks, to understand the importance of early intervention in managing and potentially modifying disease progression.

Podcast

ADVENT On Air | Expert Discussions in Dermatology

45 min

Dermatology

Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

expert video

Overview of Prurigo Nodularis Part 1: Clinical Features, Epidemiology, and Diagnosis

9 min

Dermatology

Discover key components of prurigo nodularis, including disease features, epidemiology, and practical considerations for diagnosis with Dr. Matt Zirwas in the first part of this discussion.

expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

5 min

Dermatology

Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.

expert video

An Overview of Prurigo Nodularis

38 min

Dermatology

Dr. Raj Chovatiya highlights the clinical features, epidemiology, burden, diagnosis, and pathophysiology of prurigo nodularis.

expert video

Prurigo Nodularis Myths and Facts

13 min

Dermatology

Join Dr. Sarina Elmariah as she breaks down common myths about prurigo nodularis and discusses key characteristics of disease presentation and diagnosis.

expert video

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers

10 min

Dermatology

In this ADVENT symposium at the 2024 EADV meeting, Professor Joost Meijer highlights the heterogeneous nature of BP and the resultant burden for patients.

Infographic

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

5 min

Dermatology

An infographic describing the etiology, epidemiology, challenges in diagnosis and patient burden of CPUO.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region